Sign In

Chris Gibson

Co-Founder/CEO Recursion: a biotech scaling more like a tech company - Nasdaq:RXRX | Reimagining the Future of Biotech

Chris Gibson is a highly accomplished individual with a strong background in bioengineering, entrepreneurial studies, and medicine.

He is the founder and CEO of Recursion, a pioneering digital biology company focused on revolutionizing drug discovery through the fusion of automation, artificial intelligence, and biological data.

Under his leadership, Recursion has advanced numerous clinical-stage and pre-clinical programs across various therapeutic areas, aiming to accelerate the development of life-changing medicines.

With a Ph.D. in Bioengineering from the University of Utah and a Doctor of Medicine degree, Chris brings a unique blend of scientific expertise and business acumen to his endeavors.

He is dedicated to leveraging technology and innovation to drive advancements in medicine, aiming to improve patient outcomes and reduce healthcare costs.

In addition to his work at Recursion, Chris is actively involved in mentoring and supporting emerging biotech entrepreneurs, demonstrating his commitment to nurturing the next generation of scientific innovators.

Highlights

Jan 27 · twitter

▪️ 1 in 5 people will develop cancer. ▪️ 1 of 9 men and 1 of 12 women will die from cancer. ▪️ 90% of drugs that go into clinical trials fail.

Statistics like these are what fuel all of us at Recursion to create a better way to make new medicines. A new episode of @Google's podcast Where the Internet Lives called “Mapping New Medicines” looks at the approach we’re taking – one that relies on massive proprietary datasets spanning biology, chemistry and patient data; supercomputing; and an end-to-end AI platform.

“I was frustrated by this slow, one-at-a-time approach” of traditional medicine, says co-founder and Board Chair @RecursionChris. “It felt like there had to be a better way.”

As he explains, each one of our cells contains about 20,000 genes that express around 400,000 proteins, with trillions of interactions inside the cells – “and we are made up of trillions of those cells.” That’s why biology is so complex and why, as CEO and President Najat Khan says, experts understand just 10-15% of biology. “How are we going to find a medicine if we don’t understand what’s driving a disease?” she asks.

Using that as a starting place, Recursion began employing a Google Maps approach to understanding biology – using data and AI to uncover how to take someone from disease state (Point A) to healthy state (Point B) in the fastest, best way possible.

The video takes you inside Recursion’s high throughput lab where we run millions of experiments each week, capturing cell images that are fed to @googlecloud and our supercomputer – moving more data per second through this platform than some of the leading social platforms.

As Recursion founding fellow and cancer survivor Mike Genin says, all of us love patients, are patients, or will be patients. “To dedicate our lives to changing the way drugs are discovered, to changing the future of medicine, there’s no greater pursuit.”

👉 Watch the full episode here: https://t.co/9ZMmJmMdjX

#WhereTheInternetLives #GoogleDataCenters #TechBio #data #medicine #AI #future #biology

▪️ 1 in 5 people will develop cancer.
▪️ 1 of 9 men and 1 of 12 women will die from cancer.
▪️ 90% o
Dec 1 · twitter

🔹 New data readout coming.

Join us for a webinar on Dec. 8, 8:00 am ET / 6:00 am MT / 1:00 pm GMT where we’ll share updated clinical data from our ongoing TUPELO Phase 1b/2 trial of REC-4881 in Familial Adenomatous Polyposis (FAP).

REC-4881 is a potentially first-in-disease small molecule MEK 1/2 inhibitor that was identified using Recursion’s AI platform.

✨ Presenters include: ▪️ Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer and incoming CEO and President, Recursion

▪️ David Mauro, M.D., Ph.D., Chief Medical Officer, Recursion

▪️ Elizabeth Bruckheimer, Ph.D., Ph.D., Vice President of Clinical Development, Recursion

▪️ Jessica Stout, D.O., Assistant Clinical Professor, @UUtah School of Medicine

▪️ Alfred M. Cohen, MD, FACS, FASCRS, Former CMO, Cancer Prevention Pharmaceuticals; Prior Chief, Colorectal Service, @MSKCancerCenter

✨ The webinar will be streamed live here on X as well as on: ▪️ YouTube: https://t.co/KdR7FTA1Gb

▪️ LinkedIn: https://t.co/ojGWteZ8Qo

👉 More: https://t.co/v66f7HlXRZ

🔹 New data readout coming.

Join us for a webinar on Dec. 8, 8:00 am ET / 6:00 am MT / 1:00 pm GMT
Chris Gibson
Add to my network

Location

Salt Lake City, Utah, United States